Perplexity says this about Lumakras. It might be

Quote:

---

Lumakras (sotorasib) did not have Phase III trial results available before it was presented at the European Society for Medical Oncology (ESMO) Congress in 2022. The initial FDA accelerated approval of Lumakras for KRAS G12C-mutated non-small cell lung cancer (NSCLC) was based on the Phase I/II CodeBreaK 100 trial, which was a single-arm, open-label study.

The first Phase III trial for Lumakras in NSCLC, known as CodeBreaK 200, was a randomized study comparing Lumakras to docetaxel and its data were presented at ESMO 2022 as a late-breaker oral presentation. This means that prior to its ESMO presentation, Lumakras had not reported Phase III data; only Phase I/II data were available and formed the basis for its initial regulatory submission and approval. The CodeBreaK 200 Phase III results marked the first time such data were shared publicly.

---